Anastrozole vs Liothyronine (T3)
A side-by-side research comparison of Anastrozole and Liothyronine (T3) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Anastrozole | Liothyronine (T3) |
|---|---|---|
| Full name | Anastrozole (Arimidex) | Liothyronine Sodium (Cytomel) |
| Category | Hormone Replacement | Hormone Replacement |
| Status | FDA-approved prescription | Prescription medication |
| Mechanism | Selectively and reversibly inhibits aromatase (CYP19A1), the enzyme that converts androgens to estrogens. Reduces circulating estradiol levels without affecting other steroid pathways. | Binds nuclear thyroid receptors to regulate gene transcription for basal metabolic rate, thermogenesis, protein synthesis, and carbohydrate/fat metabolism in virtually every tissue. |
| Molecular weight | 293.37 Da | 650.97 Da |
| Half-life | ~46.8 hours | ~2.5 days |
| Bioavailability | ~80-85% oral | ~95% oral |
| Typical dose | 0.25-0.5 mg | 5-25 mcg |
| Frequency | 2-3x per week | Daily (split AM/PM) |
| Route | Oral tablet | Oral tablet or sustained-release capsule |
Anastrozole reported benefits
- Estrogen control
- Reduced water retention
- Prevention of gynecomastia
- Maintained testosterone ratio
- Improved body composition
Liothyronine (T3) reported benefits
- Metabolic rate increase
- Weight loss support
- Improved energy
- Better mood
- Reduced brain fog
- Enhanced fat oxidation
Related comparisons
Research and educational reference only. Not medical advice.